Prognostic immunologic signatures in epithelial ovarian cancer

Oncogene. 2022 Mar;41(10):1389-1396. doi: 10.1038/s41388-022-02181-5. Epub 2022 Jan 14.


Epithelial Ovarian Cancer (EOC) is a deadly gynecologic malignancy in which patients frequently develop recurrent disease following initial platinum-taxane chemotherapy. Analogous to many other cancer subtypes, EOC clinical trials have centered upon immunotherapeutic approaches, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies in EOC patients have been low, evidence suggests that ovarian tumors are immunogenic and that immune-related genomic profiles can serve as prognostic markers. This review will discuss recent advances in the development of immune-based prognostic signatures in EOC that predict patient clinical outcomes, as well as emphasize specific research areas that need to be addressed to drive this field forward.

Publication types

  • Review

MeSH terms

  • Carcinoma, Ovarian Epithelial / drug therapy
  • Female
  • Humans
  • Neoplasm Recurrence, Local / pathology
  • Neoplasms, Glandular and Epithelial* / genetics
  • Neoplasms, Glandular and Epithelial* / therapy
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Prognosis